GenMont Biotech Incorporation (3164.TW)
TWD 19.95
(-1.24%)
TWD 19.95
(-1.24%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 20.11 Million TWD | -39.94% |
| 2022 | 33.48 Million TWD | 9.35% |
| 2021 | 30.62 Million TWD | -5.16% |
| 2020 | 32.28 Million TWD | 3.88% |
| 2019 | 31.08 Million TWD | 0.0% |
| 2018 | - TWD | 0.0% |
| 2017 | - TWD | 0.0% |
| 2016 | - TWD | 0.0% |
| 2015 | - TWD | 0.0% |
| 2014 | - TWD | 0.0% |
| 2013 | - TWD | 0.0% |
| 2012 | - TWD | -100.0% |
| 2011 | 484.78 Million TWD | 0.0% |
| 2010 | - TWD | 0.0% |
| 2009 | - TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 43.63 Million TWD | 116.97% |
| 2024 Q2 | 44 Million TWD | 0.84% |
| 2023 Q4 | 20.11 Million TWD | -62.57% |
| 2023 FY | 20.11 Million TWD | -39.94% |
| 2023 Q2 | 33.6 Million TWD | 0.85% |
| 2023 Q3 | 53.72 Million TWD | 59.91% |
| 2023 Q1 | 33.31 Million TWD | -0.5% |
| 2022 Q1 | 20.74 Million TWD | -32.26% |
| 2022 Q2 | 20.19 Million TWD | -2.66% |
| 2022 FY | 33.48 Million TWD | 9.35% |
| 2022 Q4 | 33.48 Million TWD | 67.74% |
| 2022 Q3 | 19.96 Million TWD | -1.13% |
| 2021 FY | 30.62 Million TWD | -5.16% |
| 2021 Q1 | 31.76 Million TWD | -1.63% |
| 2021 Q2 | 31.3 Million TWD | -1.45% |
| 2021 Q3 | 30.96 Million TWD | -1.09% |
| 2021 Q4 | 30.62 Million TWD | -1.1% |
| 2020 Q2 | 31.74 Million TWD | -1.02% |
| 2020 Q3 | 32.79 Million TWD | 3.3% |
| 2020 Q4 | 32.28 Million TWD | -1.55% |
| 2020 Q1 | 32.07 Million TWD | 3.2% |
| 2020 FY | 32.28 Million TWD | 3.88% |
| 2019 Q1 | 32.83 Million TWD | 0.0% |
| 2019 Q3 | 31.38 Million TWD | -0.96% |
| 2019 Q4 | 31.08 Million TWD | -0.97% |
| 2019 FY | 31.08 Million TWD | 0.0% |
| 2019 Q2 | 31.68 Million TWD | -3.5% |
| 2018 Q2 | - TWD | 0.0% |
| 2018 Q4 | - TWD | 0.0% |
| 2018 FY | - TWD | 0.0% |
| 2018 Q1 | - TWD | 0.0% |
| 2018 Q3 | - TWD | 0.0% |
| 2017 Q2 | - TWD | 0.0% |
| 2017 FY | - TWD | 0.0% |
| 2017 Q4 | - TWD | 0.0% |
| 2017 Q3 | - TWD | 0.0% |
| 2017 Q1 | - TWD | 0.0% |
| 2016 Q1 | - TWD | 0.0% |
| 2016 Q2 | - TWD | 0.0% |
| 2016 Q3 | - TWD | 0.0% |
| 2016 Q4 | - TWD | 0.0% |
| 2016 FY | - TWD | 0.0% |
| 2015 Q1 | - TWD | 0.0% |
| 2015 Q3 | - TWD | 0.0% |
| 2015 Q2 | - TWD | 0.0% |
| 2015 FY | - TWD | 0.0% |
| 2015 Q4 | - TWD | 0.0% |
| 2014 Q4 | - TWD | -100.0% |
| 2014 FY | - TWD | 0.0% |
| 2014 Q2 | 437.08 Million TWD | -2.71% |
| 2014 Q3 | 421.23 Million TWD | -3.63% |
| 2014 Q1 | 449.27 Million TWD | 0.0% |
| 2013 Q2 | - TWD | 0.0% |
| 2013 Q3 | - TWD | 0.0% |
| 2013 Q4 | - TWD | 0.0% |
| 2013 FY | - TWD | 0.0% |
| 2013 Q1 | - TWD | 0.0% |
| 2012 Q4 | - TWD | 0.0% |
| 2012 Q3 | - TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 Q1 | - TWD | -100.0% |
| 2012 FY | - TWD | -100.0% |
| 2011 Q1 | 479.08 Million TWD | 0.0% |
| 2011 Q2 | 480.98 Million TWD | 0.4% |
| 2011 Q3 | 482.88 Million TWD | 0.4% |
| 2011 Q4 | 484.78 Million TWD | 0.39% |
| 2011 FY | 484.78 Million TWD | 0.0% |
| 2010 FY | - TWD | 0.0% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | 116.19 Million TWD | 82.691% |
| Sinphar Pharmaceutical Co.,Ltd. | 1.49 Billion TWD | 98.654% |
| Panion & Bf Biotech Inc. | 125.41 Million TWD | 83.964% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 700 Million TWD | 97.127% |
| Abnova (Taiwan) Corporation | 2.6 Million TWD | -673.241% |
| Adimmune Corporation | 1.91 Billion TWD | 98.951% |
| Tanvex BioPharma, Inc. | 1.56 Billion TWD | 98.718% |
| Polaris Group | 352.96 Million TWD | 94.302% |
| Energenesis Biomedical CO.,LTD. | - TWD | -Infinity% |
| UnicoCell Biomed Co., Ltd. | 68.23 Million TWD | 70.526% |
| PELL Bio-Med Technology Co. Ltd. | 147.46 Million TWD | 86.362% |